Moderna Plunges 10.83% — Wall Street’s Top Short Idea or a High-Stakes FDA Trap?

Moderna investors just suffered massive whiplash. After hitting a fresh 52-week high, the stock plummeted 10.83% in a single day after JPMorgan caught the market off guard by naming it a top Q3 short idea. Despite securing a major new European vaccine contract, Wall Street is sounding the alarm over the company’s massive $3 billion R&D cash burn and a distinct lack of revenue guarantees. In this episode of Implied, we break down the reality behind the sudden crash and explore whether an upcoming August FDA decision will validate the bears—or trigger a massive short squeeze for the 130% YTD high-flyer. Tune in to find out how to play the market's most explosive biotech battle.